A MOTHER has revealed that despite losing over three stone thanks to Mounjaro, she has been hit with some unfortunate side effects. Chloe Mckernan, 32, a mum-of-two from Glasgow who is currently ...

Today marks the first official agency warning about the possibility of these drugs—specifically Mounjaro—decreasing the ...

Her openness about her journey, including using the prescription medication semaglutide, sparked a conversation about whether these types of weight loss drugs are truly safe. Kelly Clarkson’s ...

Share on Pinterest Semaglutide may be effective in treating a form of fatty liver disease, new research shows. Steve Christo – Corbis/Getty Images Semaglutide is a GLP-1 agonist medication that ...

MÁLAGA, Spain — Semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients ...

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing cardiovascular disease but not diabetes ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

The phase 3b open-label, randomized controlled trial showed that patients treated with tirzepatide vs semaglutide lost an average of 20.2% vs 13.7% of their baseline weight over the 72 weeks.

One study found that semaglutide helps to improve liver health in people with metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease. The use of semaglutide ...

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of semaglutide highlighted in a letter published in the JAMA Cardiology. The letter is ...

Adults receiving tirzepatide lost more weight and had a greater decline in waist circumference than those receiving semaglutide. The proportion of adults experiencing adverse events was similar in ...